Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Post by Craigbadon Dec 24, 2016 12:28pm

167 Views

Post# 25642616

2007

The year 2007 was a milestone year in a number of important respects. It provided a meaningful demonstration of the fact that ProMetic’s technologies have been proven and their performance characteristics validated; validated from the scientific point of view and from the regulatory point of view; validated in the marketplace where they compete; and validated by the drug developers and manufacturers who increasingly require and employ them.

Protein Technologies

Revenue Growth and High-Value Products: In 2007 we demonstrated to the market that the revenue growth promised by our protein technologies is very persuasively being carried out. We have experienced a critical mass of commercial events. In the year ahead, the steady progression of our activities in protein technologies will continue, such that we expect to reach the EBITDA-positive milestone in 2008, while generating substantial free cash flow to support the entire ProMetic group in 2009 and beyond.

ProMetic’s innovations in the area of protein technologies have created three distinct revenue paths
for the Company: (i) the purification of biotech products; (ii) removal of pathogens in blood products; and (iii) plasma-derived products.